A pooled analysis of mortality in patients with COPD receiving triple therapy versus dual bronchodilation

Marc Miravitlles; P M Calverley; Katia M.C. Verhamme; Michael  Dreher; Valentina  Bayer; Asparuh Gardev; Alberto  de la Hoz; Jadwiga A Wedzicha; David Price

A pooled analysis of mortality in patients with COPD receiving triple therapy versus dual bronchodilation

Marc Miravitlles, P M Calverley, Katia M.C. Verhamme, Michael Dreher, Valentina Bayer, Asparuh Gardev, Alberto de la Hoz, Jadwiga A Wedzicha, David Price

Research output: Contribution to conference › Abstract › peer-review

1 Downloads (Pure)

Abstract

Recent studies report a possible mortality benefit of treatment with long-acting muscarinic
antagonist (LAMA)/long-acting β2-agonist (LABA)/inhaled corticosteroid (ICS) versus LAMA/LABA combinations in patients with highly symptomatic COPD and a history of exacerbations (≥1 moderate or severe exacerbation in the previous year). We compared the time to all-cause mortality
with LAMA/LABA/ICS versus LAMA+LABA in a population of patients with predominantly moderateto-severe COPD and a predominantly lower exacerbation risk.

Original language	English
Publication status	Accepted/In press - 17 Mar 2021
Event	ATS International Conference Committee: ATS 2021 - Virtual event Duration: 14 May 2021 → 19 May 2021 https://conference.thoracic.org/

Conference

Conference	ATS International Conference Committee
Period	14/05/21 → 19/05/21
Internet address	https://conference.thoracic.org/

Access to Document

Miravitlles_et_la_ATS2021_APooledAnalysisOfMortality_AAM
Originally Published in: [Authors]. [Article Title]. [Journal Name] [Year];[Volume]:[Pages]. DOI: [Number] Copyright © 2021 by the American Thoracic Society The final publication is available at [Link].
Accepted author manuscript, 188 KBLicence: Other

Fingerprint Dive into the research topics of 'A pooled analysis of mortality in patients with COPD receiving triple therapy versus dual bronchodilation'. Together they form a unique fingerprint.

Cite this

A pooled analysis of mortality in patients with COPD receiving triple therapy versus dual bronchodilation. / Miravitlles, Marc; Calverley, P M; Verhamme, Katia M.C.; Dreher, Michael ; Bayer, Valentina ; Gardev, Asparuh; de la Hoz, Alberto ; Wedzicha, Jadwiga A; Price, David.

2021. Abstract from ATS International Conference Committee, .

Research output: Contribution to conference › Abstract › peer-review

@conference{b3983900573c4f1cbb7849be91688004,

title = "A pooled analysis of mortality in patients with COPD receiving triple therapy versus dual bronchodilation",

abstract = "Recent studies report a possible mortality benefit of treatment with long-acting muscarinicantagonist (LAMA)/long-acting β2-agonist (LABA)/inhaled corticosteroid (ICS) versus LAMA/LABA combinations in patients with highly symptomatic COPD and a history of exacerbations (≥1 moderate or severe exacerbation in the previous year). We compared the time to all-cause mortalitywith LAMA/LABA/ICS versus LAMA+LABA in a population of patients with predominantly moderateto-severe COPD and a predominantly lower exacerbation risk.",

author = "Marc Miravitlles and Calverley, {P M} and Verhamme, {Katia M.C.} and Michael Dreher and Valentina Bayer and Asparuh Gardev and {de la Hoz}, Alberto and Wedzicha, {Jadwiga A} and David Price",

year = "2021",

month = mar,

day = "17",

language = "English",

note = "ATS International Conference Committee : ATS 2021 ; Conference date: 14-05-2021 Through 19-05-2021",

url = "https://conference.thoracic.org/",

}

TY - CONF

T1 - A pooled analysis of mortality in patients with COPD receiving triple therapy versus dual bronchodilation

AU - Miravitlles, Marc

AU - Calverley, P M

AU - Verhamme, Katia M.C.

AU - Dreher, Michael

AU - Bayer, Valentina

AU - Gardev, Asparuh

AU - de la Hoz, Alberto

AU - Wedzicha, Jadwiga A

AU - Price, David

PY - 2021/3/17

Y1 - 2021/3/17

N2 - Recent studies report a possible mortality benefit of treatment with long-acting muscarinicantagonist (LAMA)/long-acting β2-agonist (LABA)/inhaled corticosteroid (ICS) versus LAMA/LABA combinations in patients with highly symptomatic COPD and a history of exacerbations (≥1 moderate or severe exacerbation in the previous year). We compared the time to all-cause mortalitywith LAMA/LABA/ICS versus LAMA+LABA in a population of patients with predominantly moderateto-severe COPD and a predominantly lower exacerbation risk.

AB - Recent studies report a possible mortality benefit of treatment with long-acting muscarinicantagonist (LAMA)/long-acting β2-agonist (LABA)/inhaled corticosteroid (ICS) versus LAMA/LABA combinations in patients with highly symptomatic COPD and a history of exacerbations (≥1 moderate or severe exacerbation in the previous year). We compared the time to all-cause mortalitywith LAMA/LABA/ICS versus LAMA+LABA in a population of patients with predominantly moderateto-severe COPD and a predominantly lower exacerbation risk.

M3 - Abstract

T2 - ATS International Conference Committee

Y2 - 14 May 2021 through 19 May 2021

ER -